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Much effort has been devoted to developing vaccines against different stages
in the life cycle of the malarial parasite. Infection is initiated by injection of
sporozoites by mosquitoes. If this stage in the life cycle can be blocked, then
infection can be prevented. Vaccines against sporozoites are based on the
following observations. A family ofanalogous surface proteins (circumsporozoite
[CS] proteins) are found on all malarial sporozoites, and contain an immunodom-
mant repeating epitope, the central third of the CS protein. Antibodies to this
repeating epitope block infection (1-4).
One antisporozoite vaccine against Plasmodium falciparum, currently being
tested in humans, has been produced as a fusion protein between the repeat
sequence of the malaria parasite [MDP(NANP),SNVDP(NANP),5NVDP] (one-
letter amino acid code) and 32 amino acids encoded by a tetracycline-resistance
gene read out of frame (tet32) (5). If the goal of vaccination is a high antibody
titer over a limited period of time, then T cell help can be supplied in the vaccine
from a carrier unrelated to the sporozoite protein itself. If boosting is desirable
from natural infection, or if cellular immunity also kills the parasites in the liver,
then T cell epitopes must derive from the parasite protein. We determined
whether the repeating peptide of parasite origin or the tet32 peptide contained
the Tcell epitope(s). This report shows that Tcell epitopes are contained within
both the repeating peptide and tet32. The immune response to the T epitopes
was under Ir gene control, mapping to the I-A and I-E regions ofthe mouse H-
2 complex, but only mice bearing the 1-A' gene responded to the T cell epitope
from the repeat. Ifan analogous situation applies in humans, boosting by natural
exposure to sporozoites, through mosquito bites, may require addition to the
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vaccine of another epitope for T cell recognition from elsewhere in the CS
protein .
Materials and Methods
Mice.
￿
H-2-congenic mice on the B10 background were bred at our breeding facility
or were purchased from The Jackson Laboratory, Bar Harbor, ME .
Antigens.
￿
The following were used : R32 tets2 , MDP(NANP), 5NVDP(NANP), 5NVDP
Tet 1-32, where Tet 1-32 refers to the first 32 amino acids encoded by a tetracycline
resistance gene, read out of frame ; R32LR, MDP(NANP), 5NVDP(NANP), SNVDPLR ;
24-mer, NP(NANP) 5NA = (NPNA)6 ; 7-mer, PNANPNA ; 11-mer, P(NANP) 2NA ; 16-
mer, NP(NANP) 5NA = (NPNA)4 ; 40-mer, (NANP), oG ; 60-mer, (NANP), SG .
Immunization.
￿
For antibody production, mice were given a primary intraperitoneal
injection of 80 ,ug of antigen emulsified in H37Ra CFA (Difco Laboratories, Detroit, MI)
on day 0, followed by secondary and tertiary intraperitoneal injections of 20 Ag ofantigen
(aqueous) on days 21 and 31 . Sera from a bleed on day 41 were used .
For T cell proliferation studies (6), 100 ug ofR32 tet32 emulsified in CFA was injected
in the base of the tail of mice on day 0 . On day 10, draining nodes were removed . Cells
were seeded at 4 x 105 cells/well (flat-bottom microtiter plates, 3596 ; Costar, Cambridge,
MA) in 0.2 ml of RPMI containing 10% FCS, 5 x 10-5 M 2-ME, penicillin, streptomycin,
and antigen . On day 5, 1 uCi of f - 'Hlthymidine (New England Nuclear, Boston, MA) was
added to quadruplicate cultures, 16 h later, cells were harvested, and incorporated sH
was assessed by ,Q emission spectroscopy .
Estimation of Specific IgG .
￿
Specific IgG was estimated by ELISA . Briefly, 60-mer (2
Ag/ml, 50,u]) was added to polyvinyl wells for 16 h . Wells were then blocked, sera added,
and a goat anti-mouse IgG coupled to alkaline phosphatase (Kirkegaard and Perry
Laboratories, Inc ., Gaithersburg, MD) was added . Finally substrate (104-105 ; Sigma
Chemical Co ., St . Louis, MO) was added, and absorbance was read at 405 rim . Sera were
tested at various dilutions and compared with a control serum defined to contain 1,000
U of specific IgG per milliliter .
Results
The influence of Ir genes on the antibody response to 24-mer (administered
without carrier) was examined initially . Different H-2-congenic mice were im-
munized, and anti-NANP specific IgG was determined (Table I) . Of the mice
examined, only those carrying the I-Ab gene produced specific antibody . These
results indicated that the 24-mer contained a T epitope capable of being seen by
mice expressingan I-Ab molecule, as well as a B epitope . As the B 10 mice express
only an I-Ab molecule and no I-E molecule, the response maps to I-Ab . It has
previously (7)been shown that (NANP) - 2 contains theB epitope, since(NANP)2
can inhibit the interaction of antisporozoite mAb and sporozoites .
To determine the minimum size of this T epitope, lymph node proliferation
assays were performed . 1310, B10.A (5R), and B10 .D2 mice were immunized
with R32 tets2 . Lymph node cells were then restimulated in vitro with different
antigens (Fig. 1) . As shown, R32 tet32 efficiently stimulated cells from all strains .
B10 .132 cells, as expected, could not be stimulated with any (NANP) constructs,
even as large as the 60-mer (n = 15) . B10 and BIO.A(5R) cells were capable of
optimal restimulation with 16-mer, moderate restimulation with 11-mer, but
could not be restimulated with 7-mer . The minimal effective T epitope is thus
between the 1 1-mer and 16-mer .
Similarly, the Ir gene control of the response to R32 tet32 was mapped (Table
II) . Mice (carrying the I-Ab gene) that responded to 24-mer also responded to70
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TABLE I
Ir Gene Control ofResponse to 24-mer
Each value represents serum from onemouse .
810
1 3 10 30 100
810"A(5R)
1 3 10 30 100
B10-D2
0
3 10 30 100
Antigen Concentration INg/mll
FIGURE 1 .
￿
B10, B10.A(5R), and B10.D2 mice were immunized in the base of the tail with
R32tet32 , as described. 10 d later, draining lymph node cells were challenged in vitro with
different concentrations of either R32tet32 (O), 60-mer (0), 40-mer (0), 16-mer (,L), 11-mer
(A), or 7-mer (EI), and proliferation wasassessed by incorporation of [3H]thymidine 4 d later .
Background cpm (in theabsence of antigen) was 17,654 for B10 cells, 15,817 for B10.A(5R)
cells, and 23,067 for B10.D2 cells . Acpm given in the figure are (cpm with antigen) - (cpm
without antigen) .
R32 tet32. This was expected since R32 tet32 contains two blocks of (NANP)15 .
However, certain strains that did not respond to 24-mer did respond to R32
tet32 (BIO.HTT, BIO.D2), whereas other strains (B10S, B10.BR, B10.GD)
responded poorly . While B10.D2 cells contain two possible class II restriction
molecules (I-Ad , I-Ed), B IO.GD cells contain only I-Ad . The differential response
between B10M and B10.GD, then, suggests that R32 tet32 contains a T
epitope(s) recognized in association with I-Ed not I-Ad . Fig. 1 shows that the T
epitope seen by B10.D2 cells is not (NANP) ,6, since these cells did not respond
to any construct of (NANP) up to n = 15 (also see Table III, below) .
The differential response of BIO.HTT to 24-mer and R32 tet32 shows that
Strain
K A B
H-2
J
alleles
E C S D
Anti-NANP
Exp . 1
IgG (U/ml)
Exp. 2
B10.S s s s s s s s s <1,<1, <1, <1,<1 ND
B10.BR k k k k k k k k <1, <l, <1, <1,<1 <1, <l, <1,<1, <1
B10.HTT s s s s k k k d <1,<1, <1, <1,<1 ND
B10.A(5R) b b b k k d d d 105, 10, <1, 164, 159 27, 10, 114, 75,2
B10 6 6 b b b b b b 80, <1, 24, 10, 252 588, 292, 751, 1789
B10.D2 d d d d d d d d <1, 3, <1, <1, <1 ND
B10.MBR b k k k k k k q ND <1, <1, <1,<1, <1
B10.A(4R) k k b b b b b b ND <1, <1, <1, <1, <1658
* See results from Table I.
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TABLE III
Definition ofNon-24-mer T Epitope(s) by Immunization with Various
Peptides
162
E,''Eps can also be a restriction element for a T epitope(s) within R32 tet32, but
distinct from the 24-mer. This Ir gene control maps to E.kE#s in the B10.HTT,
since BIOS, which expresses the same I-As molecule as BIO.HTT but expresses
no I-E molecule, does not respond. The results of Table II do not indicate
whether B10 mice are responding to a T epitope within R32 tet32 in addition to
that contained within 24-mer. The BIO.A(5R) response to R32 tet32 probably
maps to the I-A' molecule shared with the B10 strain, which does not express an
I-E molecule. However, an additional role of the E~'`E#" molecule also expressed
by the B10.A(5R) mice cannot be ruled out with available recombinant strains.
To identify more precisely the T epitope(s) in R32 tet32 that is recognized by
MOMand B10.HTT mice, these mice were immunized with R32 tet32, R32LR
(which lacks the tet32 peptide), and different constructs of (NANP), where n =
6, 10, or 15 (Table III). Neither strain ofmouse produced antibody in response
to (NANP) as large as the 60-mer, indicating that the failure to respond to 24-
mer (Table I) was not due to the small size ofthe 24-mer. Neither of the strains
that responded to R32 tet32 responded to R32LR, indicating that tet32 contained
the functional T epitope(s) for those two strains, and that the variant repeats,
NVDP, contained within R32LR, and which were absent from the 60-mer, were
not sufficient to elicit T cell help. Lymph node cell transformation studies
confirmed this finding, showing that while the 1110, BIO.HTT, and BIOM
mice, which had been immunized with R32 tet32 could all respond to R32 tet32,
only the BIO mice could respond to R32LR (data not shown). Thus, ofall strains
tested, only those mice carrying the I-Ab gene could respond to the malaria-
specificsequence present in R32 tet32, which is contained within NP(NANP)3NA.
Strain
K A B
H-2
J
alleles
E C S D
Response
to 24-
mer*
Anti-NANP
Exp. 1
IgG (U/ml)
Exp. 2
B10.S s s s s s s s s - <1, <1, <1, <1, <1 <1, <1, <1, <1
B10.BR k k k k k k k k - <1, 3, <1, <1, <1 ND
B10.HTT s s s s k k k d - 686, 91, 809, 155, 107 ND
B10.A(5R) b b b k k d d d + 451, 809, <1, 107, <1 ND
B10 b b b b b b b b + 1,180, 461, 275, 431 ND
MOM d d d d d d d d - 97, 40, 53, 78 105, 68, 101, 89, 93
B10.GD d d b b b b b b - ND 43, 4, <1, <1, <1
Immunogen
Anti-NANP
B10.D2
IgG (U/ml)
B10.HTT
R32 tets2 70, 57, 161, 153, 127 123, 379, 244, <1,
24-mer <1, <1, <1, <l, <1 <1, <1
40-mer <1, <1, <1, <1, <1 <1, <1
60-mer <1, <1, <1, <1, <1 <1, <1
R32LR <1, <1, <1, <1, <1 <1, <1GOOD ET AL .
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Discussion
Immunity to sporozoites requires constant high levels of specific antibody and
possibly non-antibody dependent cellular mechanisms of immunity (8) . To
maintain high levels of antibody after vaccination, a vaccine must have certain
properties : (a) it must contain an appropriate B epitope(s) ; (b) it must contain T
epitopes, covalently linked to the B epitopes, that are capableof being recognized
by all who receive the vaccine; (c) for natural boosting to occur, T epitopes must
derive from the organism . Because of Ir gene control (9, 10) only a subset of
individuals will respond to any given epitope .
Although human trials with R32 tet32 have only just commenced, the results
presented here from murine studies suggest that some of the above criteria may
be absent for this vaccine. Firstly, R32 tet32 is capable of stimulating significant
levels of antibody in only four of seven inbred strains of mice . These mice are
homozygous, however, at each H-2 locus, and the response to R32 tet32 in an
outbred population could be expected to be much better . Disappointingly,
however, more strains respond to T epitopes present in Tet 32 than in the
malaria-encoded sequence, R32 . Only two of nine strains of mice (representing
one of eight different possible I-A and I-Erestriction molecules, including hybrid
molecules) could respond to the malaria sequence, (NANP)6. If an analogous
situation occurs in humans, many people may not recognize the malaria T
epitope, even though they may recognize the tet32 T epitope(s), and could thus
not mount an anamnestic response to sporozoite inoculation . Although not
directly addressed here, malaria-specific T epitopes are crucial for a vaccine
reliant on high levels of cellular immunity . Studies (8) in murine malaria suggest
an important role for cellular immune mechanisms in sporozoite clearance .
The results of this study have broader implications for peptide vaccine devel-
opment in general . Peptide vaccines must contain all the relevant immunologic
information in a single sequence ofamino acids. Invariant B epitopes recognized
by protective antibodies must be covalently linked to invariant T epitopes, at
least one of which must be recognized by T cells of all who receive the vaccine.
The T and B epitopes present in the peptide must also be on the same molecule
in the organism for boosting to occur (11, 12) . Should the molecule in the
organism that contains the required B epitope contain few or no T epitopes,
then a vaccine will need to contain artificial T epitopes, and thus require
repetitive administration to boost antibody levels . This may be the case with R32
tet32 .
Summary
Different H-2 congenic strains of mice were immunized with a P . falciparum
sporozoite vaccine currently being tested in humans, or with different segments
of the vaccine molecule . Specific IgGproduction or lymph node cell proliferation
in response to different antigens was then determined . Only four of seven strains
(representing three of eight possible different class II restriction molecules)
responded to the vaccine . Of those restriction molecules, only one, I-Ab, was
associated with a response to a malaria-encoded T epitope [contained within
NP(NANP) 3NA], while the other two molecules (E~dEsd and E,''E, 35) were associ-
ated with a T cell response to a nonmalarial epitope(s) carboxyterminal to the660
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malaria sequence and encoded by a tetracycline resistance gene, read out of
frame. If an analogous situation applies in humans, natural boosting by sporo-
zoites will be very restricted. This has serious implications for the effectiveness
of the vaccine, since constant high levels of antisporozoite antibodies and possibly
antibody-independent T cell effector functions are required for immunity.
We thank Smith, Kline, and French Laboratories, Swedeland, PA for providing the
recombinant vaccine; Drs. R. Carter, I. Quakyi, N . Kumar, S. Hoffman, W. Weiss, S .
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